Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Personal CGM improves glucose control for diabetes patients

In acknowledgement of this year’s World Diabetes Day, which calls on all those responsible for diabetes care to understand diabetes and take control, Medtronic, Inc. (NYSE: MDT) highlights the growing body of clinical evidence for Personal Continuous Glucose Monitoring (CGM) in improving glucose control for diabetes patients.

16 Nov 2009

Columbia University Medical Center presents the 2009 Naomi Berrie Awards

Columbia University Medical Center will present the 2009 Naomi Berrie Awards to a nationally recognized diabetes researcher, and a promising young investigator, for their outstanding achievements in diabetes research.

16 Nov 2009

Decreased heart functions associated with fat collection in different body locations: Study

Researchers from Boston University School of Medicine (BUSM) have shown that fat collection in different body locations, such as around the heart and the aorta and within the liver, are associated with certain decreased heart functions. The study, which appears on-line in Obesity, also found that measuring a person's body mass index (BMI) does not reliably predict the amount of undesired fat in and around these vital organs.

13 Nov 2009

Canadians to celebrate World Diabetes Day in recognition of people who live with diabetes

In recognition of the ongoing commitment by millions of Canadians who build awareness of, and live with diabetes, World Diabetes Day will be celebrated on November 14. An official United Nation's World Health Day, World Diabetes Day marks the birthday of Sir Frederick Banting, who, along with Dr. Charles Best, co-discovered insulin in 1921.

13 Nov 2009

Diabetic retinopathy on the rise; dilated eye exam can help prevent vision loss

The incidence of diabetes continues to increase, particularly among adolescents and young adults. The CDC projects the number of diabetic retinopathy cases will double by 2050. On World Diabetes Day, November 14, the American Academy of Ophthalmology (Academy), through its EyeSmart™ campaign, is reminding the public that an annual dilated eye exam can help prevent vision loss in people with diabetes.

13 Nov 2009

New knowledge of basic science may be applied in future medical treatments

How does the developing pancreas in an embryo 'know' which cells are to produce insulin and which cells are to have other assignments? Researchers need to understand this if they want to be able to treat type-1 diabetes with stem cells developed into insulin-producing beta cells. At Lund University scientists have uncovered pioneering new knowledge, and are publishing it in the journal Cell.

13 Nov 2009

RemedyMD launches first nationwide diabetes registry

RemedyMD (www.RemedyMD.com), the leading provider of Patient registry software, today announced the first nationwide Type 2 Diabetes registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

13 Nov 2009

Health Canada approves ONGLYZA for type 2 diabetes treatment

Bristol-Myers Squibb Canada and AstraZeneca Canada today announced that Health Canada has approved ONGLYZA(TM) (saxagliptin) which improves all three key measures of glycemic control - hemoglobin A1c (A1c), fasting plasma glucose (FPG) and post-prandial glucose (PPG) - when taken in combination with other commonly used oral anti-diabetic agents (metformin or a sulfonylurea).

13 Nov 2009

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

13 Nov 2009

Gene variants which influence insulin metabolism can also affect birth weight

Low birth weight increases the risk of developing type 2 diabetes later in life. Until recently scientists had attributed this to maternal malnutrition during pregnancy. However, now it seems that genetic background may also play a major role. A research team of Technische Universität München and Helmholtz Zentrum München has now demonstrated, that gene variants which influence insulin metabolism can also affect birth weight.

12 Nov 2009

Impact of health insurance reform on Americans with diabetes: HHS report

As the nation marks American Diabetes Month, HHS Secretary Kathleen Sebelius released a new report today, Preventing and Treating Diabetes: Health Insurance Reform and Diabetes in America. The report comes one day after Sebelius toured the East Manatee Family Healthcare Center in Bradenton, Fla. At the center, Sebelius met with patients and Floridians who care for people with diabetes.

12 Nov 2009

CVS Caremark's medication adherence program for people with diabetes has positive impact

CVS Caremark said the company's comprehensive adherence program for people with diabetes positively impacts medication adherence for both new and continuing patients. A review of data tracking the program found that 75.6 percent of patients continuing on a diabetes therapy who participated in the adherence program maintained optimal adherence to their prescribed therapy vs. 61.2 percent in the control group.

12 Nov 2009

Common myths about sun exposure, sunscreen and vitamin D

When it comes to vitamin D, consumers are bombarded with mixed messages about the best source for this essential nutrient. While some may argue that small doses of intentional sun exposure are safe, dermatologists point out that the risk of developing skin cancer from ultraviolet (UV) radiation far outweighs the benefit of stimulating vitamin D production - particularly when enriched foods and supplements are safe and effective sources of this vitamin.

11 Nov 2009

Lesser rates of kidney/pancreas transplants for African Americans: Is physician bias the reason?

Physician bias might be the reason why African Americans are not receiving kidney/pancreas transplants at the same rate as similar patients in other racial groups. Dr. Keith Melancon, director of kidney and pancreas transplantation at Georgetown University Hospital and associate professor of surgery at Georgetown University Medical Center, and colleagues explore this phenomenon in the November issue of the American Journal of Transplantation.

10 Nov 2009

Environmental factors, obesity and diabetes: Long-term study launched

Three Singapore biomedical institutions have launched a major, long-term study of pregnant mothers and their fetuses as well as infant children to determine just how profoundly environmental factors early in life influence the onset of diseases such as obesity and diabetes in later years.

10 Nov 2009

Compugen discovers new biomarker for predisposition to type 2 diabetes using its GeneVa platform

Compugen Ltd. announced today the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes.

9 Nov 2009

Public health experts urge Congress not to overlook the needs of Americans with "morbid obesity"

As the House of Representatives and the Senate debate companion bills to make health care more affordable and accessible, a coalition of obesity and public health experts today urged Congress not to overlook the needs of the more than 15 million Americans who suffer from severe obesity and are at the greatest risk for chronic disease and death.

9 Nov 2009

Tethys Bioscience completes $25 million Series D financing

Tethys Bioscience, a privately held company, announced today that it has closed a $25 million Series D round of financing led by aeris CAPITAL AG and including Wasatch Advisors as a new investor. All current investors, including MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital participated in the round. Tethys also announced that it has appointed George Rehm, Managing Partner of aeris CAPITAL, to the Tethys Board of Directors.

9 Nov 2009

CPEX Pharmaceuticals to feature Nasulin at the Diabetes Technology Meeting

CPEX Pharmaceuticals, Inc. today announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California.

6 Nov 2009